Eligibility criteria in phase 3 randomized controlled trials in metastatic non–small cell lung cancer
Cancer · 15.03.2026 · 132 (6)
DOI: 10.1002/cncr.70361 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 16.03.2026. Verfasst von Jan Borysowski und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology, Medical University of Warsaw, Warsaw, Poland. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
Background
The purpose of this study was to assess the eligibility criteria in randomized controlled trials (RCTs) in metastatic non–small cell lung cancer (NSCLC).
Methods
Eligible trials were phase 3 RCTs of systemic treatments for metastatic NSCLC, registered with the World Health Organization International Clinical Trials Registry Platform and started between 2009 and 2023. The odds of selected eligibility criteria were determined with multivariable logistic regression. Trends in the use of the eligibility criteria over time were assessed with the Fisher's exact test.
Results
A total of 274 of 386 trials (71%) excluded patients with an Eastern Cooperative Oncology Group (ECOG) score of >1; the odds of excluding these patients were higher in RCTs of chemotherapy (adjusted odds ratio [aOR], 3.46; 95% CI [confidence interval], 1.91–6.50; p < .001) and immunotherapy (aOR, 3.31; 95% CI, 1.58–7.21; p = .001) and in recent trials (aOR, 1.83; 95% CI, 1.09–3.10; p = .02). A total of 95 of 386 trials (24.6%) had an upper age limit of 85 years or younger; this was more likely in trials performed in Asia (aOR, 8.83; 95% CI, 3.27–28.24; p < .001). The proportion of trials with eligibility criteria concerning comorbidities did not significantly decrease over time ( p > .05). None of the trials had any eligibility criteria concerning frailty.
Conclusions
The eligibility criteria in phase 3 RCTs in metastatic NSCLC continue to be strict. In some trials, judicious modifications of these criteria should be considered to improve the enrollment of clinically relevant populations of patients, especially older adults, individuals with an ECOG score of 2, and those with selected comorbidities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Immunology, Medical University of Warsaw, Warsaw, Poland.
- Institute of Human Biology and Evolution, Faculty of Biology, Adam Mickiewicz University, Poznan, Poland.
- Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
ORCID-Profile: Jan Borysowski
Zitieren
APA
Borysowski, J., Kłosowska, D., Harhala, M., Knetki-Wróblewska, M., & Krzakowski, M. (2026). Eligibility criteria in phase 3 randomized controlled trials in metastatic non–small cell lung cancer. Cancer, 132(6). https://doi.org/10.1002/cncr.70361
Vancouver
Borysowski J, Kłosowska D, Harhala M, Knetki-Wróblewska M, Krzakowski M. Eligibility criteria in phase 3 randomized controlled trials in metastatic non–small cell lung cancer. Cancer. 2026;132(6). doi:10.1002/cncr.70361
BibTeX
@article{Borysowski2026,
author = {Borysowski, Jan and Kłosowska, Danuta and Harhala, Marek and Knetki-Wróblewska, Magdalena and Krzakowski, Maciej},
title = {Eligibility criteria in phase 3 randomized controlled trials in metastatic non–small cell lung cancer},
journal = {Cancer},
year = {2026},
volume = {132},
number = {6},
doi = {10.1002/cncr.70361}
}
EUVIMED